Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Taiwan Liposome Company Ltd (4152) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7996
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taiwan Liposome Company Ltd (TLC) is a clinical-stage pharmaceutical company that develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and oncology. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan.

Taiwan Liposome Company Ltd (4152) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Licensing Agreements 15
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Equity Offering 17
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Acquisition 22
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd – Key Competitors 23
Taiwan Liposome Company Ltd – Key Employees 24
Taiwan Liposome Company Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Product News 26
10/16/2017: TLC Showcases Pain Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 26
10/11/2017: TLC to Present Update on Anesthetic Drug Candidate TLC590 at Janney’s Osteoarthritis & Pain Therapeutic Forum 27
01/09/2017: Results of Phase 1/2 Clinical Trial of TLC599 in the Treatment of Osteoarthritis of the Knee 28
Product Approvals 29
Apr 03, 2018: TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug 29
Clinical Trials 30
Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 30
Jul 11, 2017: TLC Announces Issuance of Patent for Dexamethasone Sodium Phosphate 31
Jan 03, 2017: TLC to Proceed with TLC599 Phase 2 Trial in Taiwan 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10
Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11
Taiwan Liposome and Ablynx Enter into Research Agreement 12
Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13
Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16
Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17
Taiwan Liposome to Raise Funds through Private Placement of Shares 19
Taiwan Liposome Completes Public Offering Of Shares For US$10 Million 20
Taiwan Liposome Completes Public Offering Of US$100 Million 21
Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22
Taiwan Liposome Company Ltd, Key Competitors 23
Taiwan Liposome Company Ltd, Key Employees 24
Taiwan Liposome Company Ltd, Other Locations 25
Taiwan Liposome Company Ltd, Subsidiaries 25

List of Figures
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Taiwan Liposome Company Ltd (4152):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Centene Corp (CNC):企業の財務・戦略的SWOT分析
    Centene Corp (CNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Evonik Industries Ag:企業の戦略・SWOT・財務分析
    Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report Summary Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • DHL Parcel UK Ltd:企業の戦略的SWOT分析
    DHL Parcel UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • PositiveID Corp (PSID):企業の財務・戦略的SWOT分析
    Summary PositiveID Corp (PositiveID), formerly VeriChip Corp is a life sciences tools and diagnostics company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products in …
  • Cedar Fair, L.P.:企業の戦略・SWOT・財務情報
    Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report Summary Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tampa Electric Co:発電所・企業SWOT分析
    Tampa Electric Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • PTT Public Co Ltd (PTT):石油・ガス:M&Aディール及び事業提携情報
    Summary PTT Public Co Ltd (PTT) is a state-owned integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carries out oil and natural gas exploration and production; oil refining; procurement, processing, …
  • Globo Comunicacao e Participacoes S.A.:企業の戦略的SWOT分析
    Globo Comunicacao e Participacoes S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • LGC Ltd-製薬・医療分野:企業M&A・提携分析
    Summary LGC Ltd (LGC) formerly LGC (Teddington) Limited, is a life sciences measurement and testing company which offers reference materials, genomics solutions and analytical testing products and services. Its products portfolio includes AutoGen, DNA extraction instrumentation, DNA extraction kits, …
  • Ratchaburi Electricity Generating Holding Public Co Ltd (RATCH)-エネルギー分野:企業M&A・提携分析
    Summary Ratchaburi Electricity Generating Holding Public Company Limited (RATCH) is an independent power producer that invests in subsidiaries, associates and joint ventures which operate electricity generating and related businesses. The company operates independent power producing and small power …
  • Torque Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Torque Therapeutics Inc (Torque) is an immuno-oncology company focused on developing first-in-class deep primed T Cell therapeutics to cure cancer. Its product pipeline includes Deep IL-15 used for for hematologic and solid tumors; Deep IL-12 targeting solid tumors; and small-molecule Deep T …
  • NiSource Inc.:企業の戦略・SWOT・財務情報
    NiSource Inc. - Strategy, SWOT and Corporate Finance Report Summary NiSource Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Guerbet SA (GBT):企業の財務・戦略的SWOT分析
    Guerbet SA (GBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Otrum AS:企業の戦略的SWOT分析
    Otrum AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • AutoZone, Inc.:戦略・SWOT・企業財務分析
    AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report Summary AutoZone, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Sawai Pharmaceutical Co Ltd (4555):製薬・医療:M&Aディール及び事業提携情報
    Summary Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs, and OTC drugs. It provides products in the form o …
  • National Cancer Centre Singapore-製薬・医療分野:企業M&A・提携分析
    Summary National Cancer Centre Singapore (NCCS) is a healthcare service provider that offers research and cancer treatment services. The center offers research for cancers such as breast, gynaecology, haematology, head and neck, neuro oncology, naso pharynx cancer, paediatrics, reconstructive, hepat …
  • NCI Building Systems, Inc. (NCS):企業の財務・戦略的SWOT分析
    NCI Building Systems, Inc. (NCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Imdex Limited (IMD)-石油・ガス分野:企業M&A・提携分析
    Summary Imdex Limited (Imdex) is a provider of integrated technological solutions to the mineral industry. The company offers drilling fluids, drilling equipment, advanced downhole instrumentation, data management solution and analytical software for geological modeling through its AMC and REFLEX br …
  • Factor Therapeutics Ltd (FTT):医療機器:M&Aディール及び事業提携情報
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd, is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆